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Abstract
Background: When a patient concomitantly uses two or more drugs, a drug-drug interaction (DDI) can possibly
occur, potentially leading to an increased or decreased clinical effect of a given treatment. Cancer patients are at
high risk of such interactions because they commonly receive multiple medications. Moreover, most cancer patients
are elderly and require additional medications for comorbidities. Aim of this preliminary observational study was to
evaluate the incidence of well known and established DDIs in a cohort of cancer outpatients undergoing multiple
treatments.
Methods: Anamnestic and clinical data were collected for 64 adult patients in the ambulatory setting with
malignant solid tumors who were receiving systemic anticancer treatment.
Patients also declared all drugs prescribed by other specialists or self-taken in the previous 2 weeks. DDIs were
divided into two different groups: ‘neoplastic DDIs’ (NDDIs), involving antitumoral drugs, and ‘not neoplastic DDIs’
(nDDIs), involving all other classes of drugs. The severity of DDIs was classified as major, moderate and minor,
according to the ‘Institute for Pharmacological Research Mario Negri’ definition.
Results: About 34 % of cancer outpatients within our cohort were prescribed/assumed interacting drug
combinations. The most frequent major NDDIs involved the anticoagulant warfarin (33 % of total NDDIs) that, in
association with tamoxifen, or capecitabine and paclitaxel, increased the risk of haemorrhage. About 60 % of nDDIs
involved acetylsalicylic acid.
Conclusions: Overall, 16 % of DDIs were related to an A-level strength of recommendation to be avoided. The lack
of effective communication among specialists and patients might have a role in determining therapeutic errors. Our
pilot study, although limited by a small cohort size, highlights the urgent need of implementing the clinical
management of cancer outpatients with new strategies to prevent or minimize potential harmful DDIs.
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Introduction
A drug-drug interaction (DDI) can be defined as the
pharmacological or clinical event owed to the co-exposure
of a drug with another drug or substance that modifies
the patient’s response to therapy [1, 2]. DDIs, which result
from a variety of processes including pharmaceuticals,
pharmacokinetic or pharmacodynamic mechanisms [3],
can have different outcomes by increasing or decreasing
the therapeutic efficacy, inducing adverse responses, or
resulting in a unique response that does not occur when
either agent is given alone [4]. The clinical consequences
of DDIs depend on multiple factors, including the health
status of a patient (age, comorbidity, hepatic/renal failure),
the narrow therapeutic index (NTI) of drugs involved (the
smaller is NTI the higher is the risk), genetic polymor-
phisms underlying the individual variability that influences
the response to a given treatment [5–7]. Moreover, also
the interactions between drugs and over-the-counter
(OTC) or alternative medicines and herbs should not be
underestimated [8, 9].
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Pharmacovigilance (PV) is the set of methods and
activities designed to detect, assess and prevent ad-
verse effects of drugs on the market (including DDIs)
or other human health problems resulting from their
use. In Italy, PV is required by law since 2003 (D.
Leg. 95/8 April 2003) and engages healthcare profes-
sionals to promptly report adverse reactions caused
by drugs. PV is therefore essentially an ex-post ser-
vice: it detects drugs side effects once they appeared
and keeps track of them. This traditional approach has
two main limitations: first, the reports are late, since by
definition monitoring consists in observing a reaction that
already occurred; second, monitoring is spontaneous, part
of Good Clinical Practices, and this requests a specific
knowledge of the topic. As a direct consequence, under-
reporting is a common phenomenon in all EU coun-
tries. Even in important research centers the ratio of
adverse reactions reported may not exceed 10 %
(www.farmacovigilanza.org). Delays in the identifica-
tion and underreporting of adverse reactions lead to a
poor estimate of the magnitude of the problem, which
can potentially have severe consequences on human
health.
Cancer patients are at high risk to be exposed to po-
tentially harmful DDIs because they commonly receive
multiple medications, including cytotoxic chemotherapy,
hormonal agents and supportive care drugs. In addition,
as cancer is often associated with ageing, the age-related
decline in hepatic and renal function reduces patient
ability to metabolize and clear drugs, therefore increas-
ing the potential for drug toxicity [10–12].
Moreover, the prevention of errors in the pharmaco-
logical management of cancer patients is often hampered
by an ineffective communication between specialists
and/or patients [13, 14]. A cancer patient may not report
to the oncologist a change occurred in his/her hyperten-
sion therapy or the use of complementary/alternative
medicines [15]. This ‘open loop’ management can poten-
tially cause a late detection of DDIs and have detrimen-
tal effects. [16–18].
The evidence available to guide practitioners in the
decision-making process is complex and consists of a
range of sources including adverse event database en-
tries, spontaneous or case reports, in vivo and in vitro
drug metabolism studies, and in vivo drug interaction
studies in healthy subjects and patients. In the ab-
sence of further rigorous studies to assess the clinical
significance of DDIs, an evidence-based appraisal of
the current literature is essential to guide practi-
tioners involved in patient care. So, the main aim of
our study was to assess the evidence-based level of
the DDIs detected based on the current literature and




Eligible patients were 64 adults in the ambulatory setting
with malignant solid tumors treated with systemic anti-
cancer therapies from Jan 2013 to June 2013. All pa-
tients recruited in the study had a performance status
(ECOG) less than or equal to two. Our inclusion criteria
excluded patients involved in any other clinical trial.
Anamnestic and clinical data were collected on age, sex,
diagnosis and cancer treatment, comorbidity. Patients also
declared any medication prescribed or self-taken in the
2 weeks previous to study enrollment (Table 1).
Drug-drug interaction ranking and assessment
DDIs were divided into two different groups: neoplastic
DDI (NDDIs), involving at least one antitumoral drug,
and not neoplastic DDI (nDDIs), involving all other clas-
ses of drugs.
DDIs were ranked by pharmacological mechanisms
and levels of severity [13, 19].
According to the ‘Institute for Pharmacological Re-
search Mario Negri’ definition, severity of DDIs was
classified in major, moderate and minimum, as follows:
– minimum, requiring no suspension or change in
therapy;
– moderate, requiring medical attention;
– major, resulting in clinical consequences such as
death risk and hospitalization (owing to strong
hypotension, electrolytic exchange, incoercible
nausea and belch, strong dehydration).
Table 1 Population study
Number of patients: 64
Setting: day care ambulatory
Performance status (ecog): ≤ 2
Median age: 68 years
Sex:
- Men 31 %
- Women 69 %
Type of tumors:
- Breast cancer 43 %
- Colorectal tumors 27 %
- Head and neck tumors 18 %
- Others 12 %
Concomitant disease: (average number 2)
- Cardiovascular disease 41 %
- Diabetes 26 %
- Depression 13 %
Number of medications: (average number 7)
- 2 metabolized by p-450 cyp
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An objective of our study was to describe the evidence-
based assessment of the DDIs recorded. Using a standard
information set for each DDI (eg, from product labeling,
textbooks, and the medical literature), a multidisciplinary
group (physicians, pharmacists, biologists) assessed whether
the individual drug-drug combination had an A-level
strength of recommendation to be avoided.
Drug combinations were analyzed for possible chemical
and physical incompatibility but these were excluded.
The study, performed in accordance with the Dec-
laration of Helsinki has been approved by the internal




The study enrolled 64 cancer patients with a mean age
of 68 years, 69 % women and 31 % men who were
treated in the ambulatory setting with systemic therapies
(Table 1). The most common tumors were breast (43 %),
colo-rectal (27 %) and head and neck cancer (18 %)
(Table 1). None of our patients had metastatic tumors.
Tumor features are listed in Table 2.
Drug usage and drug-drug interaction assessment
Regarding the antitumoral treatment, 61 % of patients
received i.v. chemotherapy, 29 % hormonal therapy,
10 % oral chemotherapy. Patients also declared any
medication prescribed or self-taken in the 2 weeks previ-
ous to study enrollment, including OTC medications.
Our study showed that patients received an average of
seven treatments and were administered an average of
two drugs, which are metabolized by the same hepatic
cytochrome P-450 (CYP) enzyme isoforms (Table 1).
Overall, about 34 % of the patients within our cohort
were prescribed/assumed interacting drug combinations.
The most common NDDIs involved the anticoagulant
warfarin (33 % of total NDDIs) and the antiepileptic
drug phenytoin (17 % of total NDDIs) (Table 3).
As for the first, the co-administration of warfarin and
tamoxifen was classified as a major NDDI because it re-
sulted in an increased risk of haemorrhage [20, 21]
(Table 3). Similarly, the association of warfarin with two
common antineoplastic drugs, capecitabine [22] and
paclitaxel, resulted in a moderate NDDI, with patients
requiring a decreased dosage of warfarin owing to an in-
creased risk of haemorrhage (Table 3).
For as concerns phenytoin, which can be used as anti-
convulsant for patients with brain cancer or metastases,
its association with cisplatin also resulted in a major
NDDI. Therapeutic plans based on the concomitant use
of phenytoin and cisplatin risk to fail in epilepsy control
owing to a decrease in phenytoin plasma concentration
[23, 24] (Table 3).
Other NDDIs involved the antibiotic quinolones and
cyclophosphamide; the diuretic hydrochlorothiazide and
cyclophosphamide/5-FU; the antiemetic ondansetron
and cisplatin; the diuretic furosemide and cisplatin
(Table 3).
Major nDDIs involved acetylsalicylic acid: the co-
exposure of acetylsalicylic acid and warfarin (40 % of
total nDDIs) resulted in haemorrhage risk for four pa-
tients (Table 4).
Other identified nDDIs derived from a co-exposure
between: warfarin and corticosteroids; proton pomp in-
hibitors and phenytoin; ondansetron and opioids, acetyl-
salicylic acid and ACE inhibitors/beta blockers.
By assessing the evidence-based significance of the
DDIs identified within this cohort (eg from product la-
beling, textbooks and medical literature), we found that
16 % of these DDIs were related to an A-level strength
of recommendation to be avoided. Patients involved in
DDIs of major severity and those involved in A-level
strength DDIs converged in a unique subgroup.
Discussion
About 20–30 % of adverse drug reactions are supposed
to be caused by DDIs [1, 2, 25]. DDIs are a particularly
relevant problem for cancer patients. Anticancer therap-
ies in fact are often based on the use of multiple agents,
such as cytotoxic chemotherapy, hormonal drugs and
palliative drugs used to reduce the toxicity associated
with chemotherapy. These might add to the medications
used to treat comorbid conditions such as cardiovascu-
lar, gastrointestinal, and other diseases. So, considering
that the risk to be exposed to a DDI is approximately
50 % for patients taking five medications or nearly
100 % for patients taking seven medications [25, 26],
cancer patients are at a particularly high risk to experi-
ence a DDI.
Table 2 Tumor features
Breast cancer 43 %
Invasive ductal carcinoma (IDC): Stage II (84 %) Stage III (12 %)
Profiles: Luminal A (48.8 %), Luminal B/HER2- (8.7 %), Luminal B/HER2
+ (17.4 %), HER2+/ER- (16.0 %) and Triple Negative (7.1 %);
Colorectal tumors 27 %:
Adenocarcinomas, Stage IIa (25 %) Stage IIb (75 %)
Head and neck tumors 18 %
Larynx (Squamous), Stage I (21 %) Stage II (79 %)
Pharynx (HPV+), Stage I (93 %) Stage II (7 %)
Others 12 %
Bladder (Stage I)
Prostate (Gleason score 7)
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To identify DDIs in cancer patients and prevent them
to occur, however, is challenging. First, there is the issue
of lack of communications between specialists (oncolo-
gists and family doctors or other specialists devoted to
the patient care). Second, patients could take herbs or
other remedies of which their doctors are not aware but
might interfere with their therapeutic protocols. Third,
toxic effects owed to detrimental DDIs could be errone-
ously attributed to the side effects of chemotherapy and
therefore underestimated. Finally, chemotherapy agents
are not easily manageable because of their narrow thera-
peutic index, which makes hard to modulate the dosage
without affecting efficacy or adverse effects.
Additionally, studies analyzing DDIs in cancer patients
are hampered by several limitations inherent to the
methodology involved. The major limit of the studies
that screen the patient’s medications for DDIs is the
shortage of information about the number of such inter-
actions leading to adverse clinical events.
A recent study investigated the prevalence of po-
tential DDIs among cancer patients on oral antican-
cer treatment [27]. Various DDIs were identified with
respect to widely used antineoplastic agents such as cape-
citabine, lapatinib, thalidomide, and others, interacting re-
spectively with warfarin, CYP2C8 and CYP3A4 inhibitors
and benzodiazepines or other chemotherapy drugs (i.e.
dexamethasone or doxorubicin) [25]. Therefore it is advis-
able to pay close attention to cancer patients taking these
drugs and, if feasible, safer alternatives should be pre-
scribed. In case a medication cannot be substituted, pa-
tients taking these drugs should be closely monitored for
adverse events and DDIs [26, 28].
Here, we set out to evaluate the prevalence of DDIs
in a cohort of 64 patients with malignant solid tu-
mors who were treated with systemic anticancer ther-
apies in the ambulatory setting. In particular, we
focused on the interactions between anticancer drugs
for which solid literature evidences exist. The patients
enrolled in our study were treated for breast (43 %),
colo-rectal (27 %) and head and neck cancer (18 %)
and had on average two concomitant diseases (in par-
ticular cardiovascular diseases, diabetes, depression).
Our study found that the cancer patients within our co-
hort, who had a median age of 68 years, received an aver-
age of seven treatments and were administered an average
of two drugs metabolized by the same hepatic cytochrome
P-450 (CYP) enzyme isoforms, which is consistent with
other studies analyzing polypharmacy in elderly cancer pa-
tients [29, 30]. We found that 34 % of these patients were
prescribed/assumed interacting drug combinations.
The most common NDDIs involved the anticoagulant
warfarin (33 % of total NDDIs) and the antiepileptic drug
phenytoin (16 % of total NDDIs), whereas major nDDIs
involved acetylsalicylic acid. In particular, the co-exposure
of acetylsalicylic acid and warfarin (40 % of total nDDIs)
resulted in haemorrhage risk for four patients.
Table 3 NDDIs between antineoplastic drugs and other medications
Interaction N. of cases Description Severity
Warfarin x Capecitabine/Paclitaxel 1 (head-neck) Decreased dosage of warfarin required owing to
an increased risk of haemorrhage
Moderate
Quinolones x Cyclophosphamide 2 (breast) Mucositis induced by anticancer agents might
alter the absorption of kinolon
Minor
Ondansetron x Cisplatina 1 (colorectal) Increased dosage of cisplatin required Moderate
Warfarin x Tamoxifene 4 (breast) Increased risk of haemorrhage probably due to
decreased metabolism of warfarin
Major
Phenytoin x Cisplatin 2 (colorectal) Increased dosage of phenytoin required Major
Hydrochlorothiazide x 5-FU/cyclophosphamide 1 (bladder) hydrochlorothiazide may prolong chemotherapy
induced neutropenia
Moderate
Furosemide x Cisplatin 1 (colorectal) Ototoxicity augmentation, unknown mechanism Minor
aIn therapeutic schedule high/mild belching
Table 4 nDDIs described between general and OTC medications
Interaction N. of cases Description Severity
Warfarin x corticosteroids 1 Increased or decreased in anticoagulant effect of warfarin,
unknown mechanism
Moderate
Proton pump inhibitors x phenytoin 2 Increased dosage of anticonvulsant required Minor
Ondansetron x Opioids 1 Severe constipation Moderate
Acetylsalicylic acid x Warfarin 4 Increased anticoagulant effect of warfarin Major
Acetylsalicylic acid x ACE inhibitors/beta-blockers 2 Lowering blood pressure effect of ACE inhibitors and beta-blockers
may be reduced by prostaglandin synthesis inhibition
Minor
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Patients receiving drugs interacting with warfarin face
the risk of increases in prothrombin time international
normalized ratio (PT-INR) values and subsequent haem-
orrhage. Various studies analyzed the effect of capecita-
bine and warfarin combination showing that capecitabine
affects the anticoagulant effect of warfarin not only during
the co-administered term but also after discontinuation
term, suggesting that PT INR levels should be closely
monitored in patients using these drugs together [31, 32].
Similarly, we found association of warfarin with tam-
oxifen, which is used as hormonal treatment for women
with oestrogen-receptor-positive breast cancer. Tamoxi-
fen therapy and cancer can increase the risk of venous
thromboembolism, however the concomitant use of war-
farin is contraindicated, because it increases the risk of
bleeding complications and requires consistent and care-
ful monitoring of the coagulation profile [20, 33].
So, in those cases for which it might not be possible to
recommend alternative medications, it should be neces-
sary at least to monitor carefully the status of patients
treated with the contraindicated drugs.
Aggressive dosing of phenytoin could be required to
achieve therapeutic concentrations in patients who con-
currently receive chemotherapy such as cisplatin) and/or
dexamethasone, especially in patients who fall outside the
predictive pharmacokinetic model for phenytoin. Subther-
apeutic phenytoin concentrations may be decreased by con-
comitant use of cisplatin owing to variousmechanisms and
therefore its use needs to be closely monitored [23, 24].
A-level evidence shows that concomitant use of NSAIDs
in anticoagulated carries a real risk of serious bleeding, as
well as thromboembolism. Thus, physicians should clearly
exercise extra caution with NSAIDs in patients with can-
cer, especially if they are anticoagulated. Also, cancer pa-
tients with NSAIDs should also undergo regular clinical
review, and clinicians should regularly reassess the need
for NSAID use. Finally, as a part of regular clinical assess-
ment, bleeding risk should be routinely assessed, and the
HAS-BLED score is now recommended in many guide-
lines for this purpose.
Our study showed that, based on the current evidence,
16 % of the DDIs identified in our cohort were related to
an A-level (high) strength of recommendation to be
avoided. It is likely that our findings could be extended to
other tumor types such as lung, pancreatic and other can-
cers for which patients heavily depend on chemotherapy.
The rates of DDIs is likely to vary depending on various
factors including: i) tumor stage: in our cohort we did not
have metastatic patients; patients with early stage cancer
are less likely to take multiple medications; ii) adult and
older age patients are more likely to have higher comorbidi-
ties than younger cancer patients. Nonetheless our findings
strongly suggest that the DDI issue needs to be taken in
serious consideration when dealing with cancer outpatients.
The lack of effective communication among specialists
and patients might have a role in the therapeutic errors
involving DDIs.
Conclusions
Overall, by showing that 34 % of cancer patients were pre-
scribed/assumed interacting drug combinations of which
16 % were recommended to be avoided, our data suggest
that, not only it is important to improve our knowledge
regarding the effects derived from a co-exposure to drugs,
but it is very urgent to implement the clinical manage-
ment of patients based on the current evidence of well-
established and potentially harmful DDIs. This could be
achieved by improving the communication among all the
doctors taking care of a patient or establishing a ‘connect-
ivity unit’. Some studies in particular propose that the role
of clinical pharmacists, possibly with a specific training in
oncology [34], could be implemented to reduce medication
related problems and optimize therapeutic treatments [35].
Alternatively, it should be considered the opportunity to
generate new fully-automated methods, through the use of
modern information technology, to control the pharmaco-
logical risk that are independent from medical communi-
cation, in order to decrease the number of toxicological
drug-related consequences. An example in this direction is
the development of specific databases to detect DDIs in
primary healthcare [36]. Furthermore, all the stakeholders
should commit to sensitize patients, through ad hoc health
education campaigns, in order to reduce potential causes
of interference with medications for chemotherapy or co-
morbidities, such as OTC, herbs or other remedies.
Ultimately, it will be important to investigate more
thoroughly the real impact of DDIs in oncology, by
assessing how the common DDIs involving genetic mod-
ifications can occur and also the economic impact of
DDIs on the health system. For these purposes large rep-
resentative epidemiologic studies are needed [37].
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